Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one ...

Compass Therapeutics has announced top-line data from its ongoing COMPANION-002 trial investigating its antibody-based ...

Equillium’s phase 3 graft-versus-host disease (GVHD) trial has missed its primary endpoint and two key secondary objectives.

Patients treated with monoclonal antibodies directed against immunological molecules may be viewed as being similar to patients with primary immunodeficiency (PID) of the corresponding antibody ...

COVID-19 Vaccine Side Effects and Long-Term Neutralizing Antibody Response: A Prospective Cohort ... study in 2021 on individuals receiving the primary vaccine series, making the generalizability ...